PROMES-URONCT06738797
Association Between the SPHERTEST in Vitro Test and Response to Checkpoint Inhibitor Treatments in Patients With Advanced or Metastatic Urothelial Carcinoma
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Centre Hospitalier Universitaire de Nīmes
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jun 2029 to Jun 2030 Show 4 more changesShow less
- Enrollment increased: 32 → 60 participants
- Eligibility criteria expanded, about 8 words
- Study sites: 5 to 6
- Secondary endpoints: details revised at 22 of 30 entries
- Notable Primary and study completion dates: Jun 2027 to Jun 2029v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Dec 2024 to Dec 12, 2024
- Secondary endpoints: 34 to 30
- Site details revised at 5 of 5 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
SPHERTEST measurement of potential therapeutic efficacy
Timeframe: Day 0
Progression-free survival
Timeframe: Month 12
Secondary (25)
Histology of cells
Presence of an aggressive minority component
Type of other component
Tumor grade
PD1/PDL1 status
Show 20 moreShow less
PDL1 score
Type of metastatic involvement
Primary tumor site
Hemoglobin level
Lactate dehydrogenase level
C-reactive protein level
Neutrophil count
Lymphocyte count
Number of lines of systemic treatment received in the metastatic phase
Type of platinum salt received prior to immunotherapy
Treatment regimen prior to anti-PD1 therapy
Current treatment: whether treatment is combined with another molecule
Antibiotics in the previous month
Corticosteroid therapy > 10 mg prednisolone equivalent at immunotherapy initiation
Taking an immunosuppressant other than corticosteroid therapy at immunotherapy initiation
Any comedication at immunotherapy initiation
Patient functioning level
BCG vaccine
Mitomycin therapy
History of auto-immune disease
Arms and interventions
Patients with urothelial carcinoma
Diagnostic tests: SPHERTEST test
Sites
6 sites in 1 country